BTAI BioXcel Therapeutics

BioXcel Therapeutics to Participate in Two Upcoming Healthcare Investor Conferences

BioXcel Therapeutics to Participate in Two Upcoming Healthcare Investor Conferences

NEW HAVEN, Conn., May 04, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that Dr. Vimal Mehta, Founder and Chief Executive Officer of BioXcel, will participate in two upcoming virtual healthcare investor conferences.

Presentation Details:

Event: BofA Securities 2021 Virtual Health Care Conference

Format: Fireside Chat

Date: Tuesday, May 11, 2021

Time: 8:45 AM ET



Event: UBS Global Healthcare Virtual Conference

Format: Corporate Presentation

Date: Tuesday, May 25, 2021

Time: 2:00 PM ET

Live webcasts from the BofA and UBS presentations and accompanying presentation materials will be accessible through the Investors section of the Company's website at . Following the conferences, the webcasts will be archived on the BioXcel Therapeutics, Inc. website for at least 30 days.

BioXcel Therapeutics, Inc.

BioXcel Therapeutics, Inc. is a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. BioXcel's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. BioXcel's two most advanced clinical development programs are BXCL501, an investigational, proprietary, orally dissolving thin film formulation of dexmedetomidine for the treatment of agitation and opioid withdrawal symptoms, and BXCL701, an investigational, orally administered, systemic innate immunity activator in development for the treatment of aggressive forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint inhibitors. For more information, please visit .

BioXcel Therapeutics, Inc.



Investor Relations:

Mary Coleman

BioXcel Therapeutics, VP of Investment Relations

 

1.475.238.6837



John Graziano

Solebury Trout

 

1.646.378.2942 



Media:

Julia Deutsch

Solebury Trout

 

1.646.378.2967



EN
04/05/2021

Underlying

BTAIBioXcel Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BioXcel Therapeutics

 PRESS RELEASE
Free
BTAI BioXcel Therape...

BioXcel Therapeutics to Host Virtual Roundtable Featuring Leading Medi...

BioXcel Therapeutics to Host Virtual Roundtable Featuring Leading Medical Experts Addressing Latest Developments in Treatment of Acute Agitation in Alzheimer’s Dementia Discussion will focus on the high unmet need and the lack of FDA-approved treatment options associated with acute agitation episodes in Alzheimer’s dementia Large patient population affected by Alzheimer’s agitation, with approximately ~100 million annual episodes1 KOL Roundtable to be held on Friday, February 27, at 2:00 p.m. EST NEW HAVEN, Conn., Feb. 19, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BT...

February 19, 2026 1 EN
 PRESS RELEASE
Free
BTAI BioXcel Therape...

BioXcel Therapeutics Completes Market Opportunity Assessment and Advan...

BioXcel Therapeutics Completes Market Opportunity Assessment and Advances Commercialization Plans for IGALMI® in the At-Home Setting Third party commercial assessment shows larger than expected potential total addressable market for IGALMI® in the at-home setting Strong prescriber interest, patient demand, and positive payer feedback on formulary coverage NEW HAVEN, Conn., Feb. 12, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company built on artificial intelligence (“AI”) to develop transformative medicines in neuroscience, today announced th...

February 12, 2026 1 EN
 PRESS RELEASE
Free
BTAI BioXcel Therape...

BioXcel Therapeutics Submits Supplemental New Drug Application to U.S....

BioXcel Therapeutics Submits Supplemental New Drug Application to U.S. Food and Drug Administration for IGALMI® Label Expansion in the At-Home Setting sNDA submission supports the acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home (outpatient) setting with IGALMI® Submission timeline supports potential approval of IGALMI® label expansion as early as year-end 2026 NEW HAVEN, Conn., Jan. 20, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company built on artificial intelligence (“AI”) to develop transform...

January 20, 2026 1 EN
 PRESS RELEASE
Free
BTAI BioXcel Therape...

BioXcel Therapeutics Expands Leadership Team to Prepare for Launch of ...

BioXcel Therapeutics Expands Leadership Team to Prepare for Launch of IGALMI® in the At-Home Setting Mark Pavao to Join BioXcel Therapeutics as Interim Chief Commercial Officer Mr. Pavao Brings Deep Experience in Neuroscience Sales and Marketing to Support Potential Launch of IGALMI® in At-Home Setting as Early as Year-End 2026 BioXcel Therapeutics on Track to Submit a sNDA for IGALMI® this Month NEW HAVEN, Conn., Jan. 12, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company built on artificial intelligence (“AI”) to develop transformative med...

January 12, 2026 1 EN
 PRESS RELEASE
Free
BTAI BioXcel Therape...

BioXcel Therapeutics Planning to Submit sNDA This Month Seeking FDA Ap...

BioXcel Therapeutics Planning to Submit sNDA This Month Seeking FDA Approval for At-Home Use of IGALMI® Company remains focused on potential approval and launch of IGALMI® for the acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home setting NEW HAVEN, Conn., Jan. 07, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company built on artificial intelligence (“AI”) to develop transformative medicines in neuroscience, today announced that it plans to submit a supplemental New Drug Application (sNDA) this month ...

January 7, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch